Skip to main content
EyePoint Pharmaceuticals, Inc. logo

EyePoint Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · EYPT ISIN · US74440J1016 LEI · 549300QE1RU34T50MR69 US Manufacturing
Open in API
Filings indexed 1,019 across all filing types
Latest filing 2017-09-11 Earnings Release
Country US United States of America
Listing US EYPT

About EyePoint Pharmaceuticals, Inc.

https://eyepointpharma.com/

EyePoint Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for serious retinal diseases. The company leverages its proprietary Durasert E™ technology, a bio-erodible platform for sustained intraocular drug delivery, to create durable therapies. Its lead investigational product, DURAVYU™ (EYP-1901), combines the tyrosine kinase inhibitor vorolanib with the Durasert E™ system for the potential treatment of VEGF-mediated retinal diseases. The company's goal is to improve patient outcomes and reduce treatment burden by providing long-lasting treatments for chronic eye conditions.

Recent filings

Filing Released Lang Actions
FORM 8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated September 11, 2017, reporting the results of operations and financial condition for the fiscal fourth quarter and fiscal year ended June 30, 2017. It specifically states that it includes a press release announcing these results. The document is relatively short (3203 characters) and primarily serves to announce the earnings release rather than containing detailed financial statements or analysis itself. According to the rules, initial announcements of quarterly or periodical financial results (key highlights only) are classified as Earnings Release (ER). Therefore, this document is best classified as an Earnings Release (ER).
2017-09-11 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content describes the entry into a definitive material agreement (a collaboration agreement amendment) between pSivida Corp. and Alimera Sciences. It includes details about licensing, royalties, and marketing rights. There are no financial statements or comprehensive financial data presented, only a description of the agreement and a reference to a press release. The document is not an annual or quarterly report, nor is it an earnings release or management discussion. It is a regulatory filing announcing a material event. Therefore, the appropriate classification is Regulatory Filings (RNS). The document length is 6621 characters, which is sufficient for a substantive announcement but does not contain financial statements or detailed financial analysis.
2017-07-10 English
8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated June 27, 2017, reporting the appointment of a new director to the Board of Directors and the adoption of a Short Term Incentive Plan by the Compensation Committee. The key content is about changes in the company's board and management, specifically the appointment of Kristine Peterson as a director and details about the incentive plan. There are no financial statements or earnings data presented, nor is this a report of voting results or a regulatory certification. The primary focus is on management changes and related governance matters. Therefore, the document fits best under the category of Board/Management Information (MANG). The document length (5662 characters) and content confirm it is not a brief announcement or a report publication notice but a substantive filing about management changes.
2017-06-30 English
FORM 3 SUBMISSION
Director's Dealing
2017-06-30 English
FORM 4 SUBMISSION
Director's Dealing
2017-06-29 English
FORM 4 SUBMISSION
Director's Dealing
2017-06-29 English

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.